212 related articles for article (PubMed ID: 28477059)
21. The prognostic and predictive value of serum CA19.9 in pancreatic cancer.
Humphris JL; Chang DK; Johns AL; Scarlett CJ; Pajic M; Jones MD; Colvin EK; Nagrial A; Chin VT; Chantrill LA; Samra JS; Gill AJ; Kench JG; Merrett ND; Das A; Musgrove EA; Sutherland RL; Biankin AV;
Ann Oncol; 2012 Jul; 23(7):1713-22. PubMed ID: 22241899
[TBL] [Abstract][Full Text] [Related]
22. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
[TBL] [Abstract][Full Text] [Related]
23. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
24. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer.
Chadha AS; Kocak-Uzel E; Das P; Minsky BD; Delclos ME; Mahmood U; Guha S; Ahmad M; Varadhachary GR; Javle M; Katz MH; Fleming JB; Wolff RA; Crane CH; Krishnan S
Acta Oncol; 2015 Jul; 54(7):971-8. PubMed ID: 25608822
[TBL] [Abstract][Full Text] [Related]
25. CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer.
Mie T; Ozaka M; Okamoto T; Takeda T; Ushida Y; Mori C; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Sasaki T; Inoue Y; Takahashi YU; Sasahira N
In Vivo; 2022; 36(6):2844-2851. PubMed ID: 36309391
[TBL] [Abstract][Full Text] [Related]
26. Relationship between S100A4 protein expression and pre-operative serum CA19.9 levels in pancreatic carcinoma and its prognostic significance.
Jia F; Liu M; Li X; Zhang F; Yue S; Liu J
World J Surg Oncol; 2019 Sep; 17(1):163. PubMed ID: 31526392
[TBL] [Abstract][Full Text] [Related]
27. Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients.
Song JY; Chen MQ; Guo JH; Lian SF; Xu BH
Medicine (Baltimore); 2018 Jan; 97(4):e9707. PubMed ID: 29369199
[TBL] [Abstract][Full Text] [Related]
28. A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer.
Chen Y; Shao Z; Chen W; Xie H; Wu Z; Qin G; Zhao N
Oncotarget; 2017 May; 8(18):29925-29934. PubMed ID: 28404893
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Significance of a Minute Amount of Ascites During Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Shinoto M; Nakamura K; Shioyama Y; Sasaki T; Nishie A; Asayama Y; Ohga S; Yoshitake T; Terashima K; Asai K; Matsumoto K; Honda H
Anticancer Res; 2016 Apr; 36(4):1879-84. PubMed ID: 27069174
[TBL] [Abstract][Full Text] [Related]
31. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer.
Yang GY; Malik NK; Chandrasekhar R; Ma WW; Flaherty L; Iyer R; Kuvshinoff B; Gibbs J; Wilding G; Warren G; May KS
J Gastrointest Oncol; 2013 Dec; 4(4):361-9. PubMed ID: 24294507
[TBL] [Abstract][Full Text] [Related]
32. High preoperative serum CA19-9 level is predictive of poor prognosis for patients with colorectal liver oligometastases undergoing hepatic resection.
Lu Z; Peng J; Wang Z; Pan Z; Yuan Y; Wan D; Li B
Med Oncol; 2016 Nov; 33(11):121. PubMed ID: 27722895
[TBL] [Abstract][Full Text] [Related]
33. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype.
Luo G; Liu C; Guo M; Long J; Liu Z; Xiao Z; Jin K; Cheng H; Lu Y; Ni Q; Yu X
Cancer Lett; 2017 Jan; 385():46-50. PubMed ID: 27840089
[TBL] [Abstract][Full Text] [Related]
34. The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer.
Månsson C; Nilsson A; Urdzik J; Karlson BM
Anticancer Res; 2019 Nov; 39(11):6193-6196. PubMed ID: 31704847
[TBL] [Abstract][Full Text] [Related]
35. Survival and prognostic factors of unresectable pancreatic cancer.
Park JK; Yoon YB; Kim YT; Ryu JK; Yoon WJ; Lee SH
J Clin Gastroenterol; 2008 Jan; 42(1):86-91. PubMed ID: 18097296
[TBL] [Abstract][Full Text] [Related]
36. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.
Ikeda M; Ioka T; Ito Y; Yonemoto N; Nagase M; Yamao K; Miyakawa H; Ishii H; Furuse J; Sato K; Sato T; Okusaka T
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):163-9. PubMed ID: 22677367
[TBL] [Abstract][Full Text] [Related]
37. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
[TBL] [Abstract][Full Text] [Related]
38. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy.
van Veldhuisen E; Vogel JA; Klompmaker S; Busch OR; van Laarhoven HWM; van Lienden KP; Wilmink JW; Marsman HA; Besselink MG
HPB (Oxford); 2018 Jul; 20(7):605-611. PubMed ID: 29475787
[TBL] [Abstract][Full Text] [Related]
39. Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy.
Cho WK; Yu JI; Park HC; Lim DH; Kim TH; Chie EK
Tumori; 2021 Jun; 107(3):247-253. PubMed ID: 32646298
[TBL] [Abstract][Full Text] [Related]
40. [Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].
Ma R; Zhang H; Zou L; Qu Y
Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):125-30. PubMed ID: 25877610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
